Please, it's not proof at all.
The only cost issue is the requirement to pour significant capital into a production facility in Dubai due to legislative restrictions.
They can't import the vaccine from their current manufacturing sites and it doesn't make sense to build a new one when they already have others that can cover that region once approved.
PRR's cost of goods is much less than that of DNDN's. They won't have the same profitability issues. This has already been discussed.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $379.7M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 27.0¢ | 26.0¢ | $1.129M | 4.264M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 31426 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 37000 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| IMM (ASX) Chart |